Skip to main content

Advertisement

SpringerLink
Log in

Increasing contralateral mastectomy use at diagnosis: Surgical prevention of contralateral breast cancer

  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Patients with unilateral breast cancer are at increased risk for developing contralateral breast cancer (CBC). The annual risk of clinically detected metachronous CBC is about 0.6%. Some patients choose contralateral prophylactic mastectomy (CPM) to prevent CBC. Recent studies reported that the CPM rates have markedly increased in recent years in the United States. The risk of CBC is reduced by about 95% after CPM. Because risk of systemic metastases often exceeds risk of CBC, most patients will not experience any survival benefit from CPM. Moreover, CPM is irreversible and not risk-free. Alternatives to CPM include surveillance with clinical breast examination, mammography, and possibly breast MRI. Endocrine therapy with tamoxifen or aromatase inhibitors significantly reduces risk of CBC and may be more acceptable than CPM for some patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Robbins GF, Berg JW: Bilateral primary breast cancer: a prospective clinicopathological study. Cancer 1964, 17:1501–1527.

    Article  PubMed  CAS  Google Scholar 

  2. Storm HH, Jensen OM: Risk of contralateral breast cancer in Denmark 1943–80. Br J Cancer 1986, 54:483–492.

    PubMed  CAS  Google Scholar 

  3. Prior P, Waterhouse JA: The incidence of bilateral breast cancer: II. A proposed model for the analysis of coincidental tumours. Br J Cancer 1981, 43:615–622.

    PubMed  CAS  Google Scholar 

  4. Adami HO, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based casecontrol study. Cancer 1985, 55:643–647.

    Article  PubMed  CAS  Google Scholar 

  5. Vaittinen P, Hemminki K: Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 2000, 88:998–1002.

    Article  PubMed  CAS  Google Scholar 

  6. Peralta EA, Ellenhorn JD, Wagman LD, et al.: Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 2000, 180:439–445.

    Article  PubMed  CAS  Google Scholar 

  7. McDonnell SK, Schaid DJ, Myers JL, et al.: Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001, 19:3938–3943.

    PubMed  CAS  Google Scholar 

  8. Herrinton LJ, Barlow WE, Yu O, et al.: Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005, 23:4275–4286.

    Article  PubMed  Google Scholar 

  9. van Sprundel TC, Schmidt MK, Rookus MA, et al.: Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005, 93:287–292.

    Article  PubMed  Google Scholar 

  10. Goldflam K, Hunt KK, Gershenwald JE, et al.: Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer 2004, 101:1977–1986.

    Article  PubMed  Google Scholar 

  11. Lehman CD, Gatsonis C, Kuhl CK, et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007, 356:1295–1303.

    Article  PubMed  CAS  Google Scholar 

  12. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 2003, 56:1038–1045.

    Article  PubMed  Google Scholar 

  13. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676–689.

    Article  PubMed  CAS  Google Scholar 

  14. Metcalfe K, Lynch HT, Ghadirian P, et al.: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328–2335.

    Article  PubMed  CAS  Google Scholar 

  15. Tuttle TM, Habermann EB, Grund EH, et al.: Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 2007, 25:5203–5209.

    Article  PubMed  Google Scholar 

  16. Sorbero ME, Dick AW, Burke Beckjord E, et al.: Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009, 16:1597–1605.

    Article  PubMed  Google Scholar 

  17. Metcalfe KA, Lubinski J, Ghadirian P, et al.: Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008, 26:1093–1097.

    Article  PubMed  Google Scholar 

  18. Black WC, Nease RF Jr, Tosteson AN: Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995, 87:720–731.

    Article  PubMed  CAS  Google Scholar 

  19. Alexander NE, Ross J, Sumner W, et al.: The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med 1996, 11:92–97.

    Article  PubMed  CAS  Google Scholar 

  20. Partridge A, Adloff K, Blood E, et al.: Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 2008, 100:243–251.

    Article  PubMed  Google Scholar 

  21. Rakovitch E, Franssen E, Kim J, et al.: A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 2003, 77:285–293.

    Article  PubMed  Google Scholar 

  22. Lostumbo L, Carbine N, Wallace J, et al.: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004, 4:CD002748.

    PubMed  Google Scholar 

  23. Schrag D, Kuntz KM, Garber JE, et al.: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 Mutations. JAMA 2000, 283:617–624.

    Article  PubMed  CAS  Google Scholar 

  24. Woerdeman LA, Hage JJ, Smeulders MJ, et al.: Skin-sparing mastectomy and immediate breast reconstruction by use of implants: an assessment of risk factors for complications and cancer control in 120 patients. Plast Reconstr Surg 2006, 118:321–330.

    Article  PubMed  CAS  Google Scholar 

  25. Frost MH, Slezak JM, Tran NV, et al.: Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005, 23:7849–7856.

    Article  PubMed  Google Scholar 

  26. Montgomery LL, Tran KN, Heelan MC, et al.: Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol 1999, 6:546–552.

    Article  PubMed  CAS  Google Scholar 

  27. Geiger AM, West CN, Nekhlyudov L, et al.: Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 2006, 24:1350–1356.

    Article  PubMed  Google Scholar 

  28. Altschuler A, Nekhlyudov L, Rolnick S, et al.: Positive, negative, and disparate women’s differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J 2008, 14:25–23.

    Article  PubMed  Google Scholar 

  29. Metcalfe K, Esplen MJ, Goel V, et al.: Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004, 13:14–25.

    Article  PubMed  Google Scholar 

  30. Ciatto S, Ambrogetti D, Bonardi R, et al.: Prognostic impact of early detection of contralateral primary breast cancer. Tumori 1990, 76:370–373.

    PubMed  CAS  Google Scholar 

  31. Mellink WA, Holland R, Hendriks JH, et al.: The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 1991, 67:1844–1848.

    Article  PubMed  CAS  Google Scholar 

  32. Fisher B, Redmond C: New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991, 83:1278–1280.

    Article  PubMed  CAS  Google Scholar 

  33. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992, 11:117–120.

    PubMed  Google Scholar 

  34. Rutqvist LE, Cedermark B, Glas U, et al.: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991, 83:1299–1306.

    Article  PubMed  CAS  Google Scholar 

  35. Baum M, Budzar AU, Cuzick J, et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131–2139.

    Article  PubMed  CAS  Google Scholar 

  36. Meakin JW, Hayward JL, Panzarella T, et al.: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1996, 37:11–19.

    Article  PubMed  CAS  Google Scholar 

  37. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 351:1451–1467.

  38. Tuttle TM, Jarosek S, Habermann E, et al.: Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009, 27:1362–1367.

    Article  PubMed  Google Scholar 

  39. Fisher ER, Dignam J, Tan-Chiu E, et al.: Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999, 86:429–438.

    Article  PubMed  CAS  Google Scholar 

  40. Fisher B, Dignam J, Wolmark N, et al.: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993–2000.

    Article  PubMed  CAS  Google Scholar 

  41. Houghton J, George WD, Cuzick J, et al.: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95–102.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN, 55424, USA

    Todd M. Tuttle

Authors
  1. Todd M. Tuttle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amanda Arrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natasha Rueth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Todd M. Tuttle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tuttle, T.M., Arrington, A. & Rueth, N. Increasing contralateral mastectomy use at diagnosis: Surgical prevention of contralateral breast cancer. Curr Breast Cancer Rep 1, 162–166 (2009). https://doi.org/10.1007/s12609-009-0023-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-009-0023-3

Keywords

Search

Navigation